We have so little information about what is really going on that it's hard to venture a guess as to whether they are near a joint venture deal (hopefully still left on the table by a big pharma or three after 2 1/2 years of Salari's skillful negociations), or what Cortecs is up to, or whether this financing is simply a security blanket of sorts. I even wonder whether this private placement would be going to people who may have shorted millions of shares at much higher prices from offshore accounts, which Salari himself had repeatedly suggested existed, who could then safely cover their positions with no risk whatsoever. See, this is what happens when management has no respect for their noninstitutional shareholders, they begin to think up all sorts of scenarios. Meanwhile Rothchilds' Asset Management has a seat on the board of directors so they (and Goldman Sachs) probably know everything that's going on in a very timely fashion.
By the way, if you want to make your views and suggestions known to McBeast, I mean McBeath, the new CEO, his e-mail address is info@inflazyme.com. At least that's what I was told. I haven't e-mailed my views about their shareholder communications or questions about the status of things we have all discussed and I encourage everyone to do so so they understand that there are real concerned people among their shareholding public.
One more thing. The phone number of Dr. Michael Flynn, who is listed as President of Cortecs, is 44-181-232-1900. It's in the UK. I don't want to call their project manager, Phil Goodwin, who I spoke with ~3-4 months ago as he seemed testy at that time. I'm going to try to get hold of Flynn, and if anyone here feels like, PLEASE DO. If I talk with him and get anything intelligible, I'll post it. |
